GlassScriptPhysician profile
Halim N Charbel
NPI 1740431501
$88,449.21
in general payments reported to CMS, 2019-2025
37 companies · $74K in 2025
The $74K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,800 · 2020: $1,049 · 2021: $807 · 2022: $3,476 · 2023: $1,454 · 2024: $2,688 · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Food and Beverage: $5,954 · Travel and Lodging: $5,603 · Consulting Fee: $2,000 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,750.00 |
| Food and Beverage | $5,953.59 |
| Travel and Lodging | $5,603.48 |
| Consulting Fee | $2,000.00 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $75,332.99 | 2019-2025 | Overstitch Endoscopic Suturing System, Orbera Intragastric Balloon System, General - Therapies |
| Apollo Endosurgery US INC | $4,635.59 | 2019-2023 | Overstitch Endoscopic Suturing System |
| Allergan, INC. | $2,772.36 | 2019-2020 | |
| Abbvie INC. | $1,214.35 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $717.99 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $576.91 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $340.45 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $320.16 | 2022-2025 | Wegovy, Saxenda |
| Qol Medical, LLC | $284.69 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $205.31 | 2019-2025 | Eohilia, Entyvio |
| Gilead Sciences, INC. | $203.61 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $198.27 | 2019-2024 | Linzess |
| Celgene Corporation | $191.89 | 2021-2023 | Zeposia |
| Genzyme Corporation | $158.55 | 2022-2025 | |
| Trevena, INC. | $132.22 | 2022-2023 | Olinvyk |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $124.94 | 2019 | |
| Lilly USA, LLC | $116.82 | 2024-2025 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $106.55 | 2022-2024 | Dupixent |
| Redhill Biopharma INC. | $100.08 | 2021-2025 | Talicia |
| Braintree Laboratories, INC. | $98.16 | 2020-2024 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $97.27 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $67.67 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $66.13 | 2023-2024 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $59.92 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $57.89 | 2022-2023 | |
| Foundation Medicine, INC. | $46.75 | 2019 | |
| Endogastric Solutions, INC | $30.86 | 2019 | |
| Ambu INC. | $26.56 | 2022 | |
| Pfizer INC. | $24.73 | 2025 | |
| Digestive Care, INC. | $24.54 | 2024 | Pertzye |
| Aimmune Therapeutics, INC. | $22.40 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $19.23 | 2025 | Givlaari |
| Daiichi Sankyo INC. | $17.82 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.47 | 2019 | |
| Olympus America INC. | $15.99 | 2024 | Endoclot Phs |
| Ucb, INC. | $12.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halim Charbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.